Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma
- PMID: 33923385
- PMCID: PMC8071488
- DOI: 10.3390/jcm10081715
Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and a leading cause of cancer-related deaths worldwide. Although much progress has been made in HCC drug development in recent years, treatment options remain limited. The major cause of HCC is chronic hepatitis B virus (HBV) infection. Despite the existence of a vaccine, more than 250 million individuals are chronically infected by HBV. Current antiviral therapies can repress viral replication but to date there is no cure for chronic hepatitis B. Of note, inhibition of viral replication reduces but does not eliminate the risk of HCC development. HBV contributes to liver carcinogenesis by direct and indirect effects. This review summarizes the current knowledge of HBV-induced host epigenetic alterations and their association with HCC, with an emphasis on the interactions between HBV proteins and the host cell epigenetic machinery leading to modulation of gene expression.
Keywords: HBx; epidrugs; epigenetic regulation; hepatitis B virus; hepatocellular carcinoma; virus–host interactions.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the writing of the manuscript, or in the decision to publish the review.
Figures



Similar articles
-
The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.J Pathol. 2015 Jan;235(2):355-67. doi: 10.1002/path.4434. J Pathol. 2015. PMID: 25196558 Review.
-
Hepatitis B Virus-Associated Hepatocellular Carcinoma.Adv Exp Med Biol. 2017;1018:11-21. doi: 10.1007/978-981-10-5765-6_2. Adv Exp Med Biol. 2017. PMID: 29052129 Review.
-
T-cell therapy for chronic viral hepatitis.Cytotherapy. 2017 Nov;19(11):1317-1324. doi: 10.1016/j.jcyt.2017.07.011. Epub 2017 Aug 25. Cytotherapy. 2017. PMID: 28847469 Review.
-
Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.Oncotarget. 2021 Nov 23;12(24):2421-2433. doi: 10.18632/oncotarget.28077. eCollection 2021 Nov 23. Oncotarget. 2021. PMID: 34853663 Free PMC article.
-
Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development.Dig Dis. 2013;31(1):138-51. doi: 10.1159/000347209. Epub 2013 Jun 17. Dig Dis. 2013. PMID: 23797136 Review.
Cited by
-
Advancing therapeutic vaccines for chronic hepatitis B: Integrating reverse vaccinology and immunoinformatics.World J Hepatol. 2025 Jul 27;17(7):107620. doi: 10.4254/wjh.v17.i7.107620. World J Hepatol. 2025. PMID: 40747216 Free PMC article. Review.
-
Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA.PLoS Pathog. 2022 Jun 9;18(6):e1010576. doi: 10.1371/journal.ppat.1010576. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35679251 Free PMC article.
-
Design of multi-epitope-based therapeutic vaccine candidates from HBc and HBx proteins of hepatitis B virus using reverse vaccinology and immunoinformatics approaches.PLoS One. 2024 Dec 6;19(12):e0313269. doi: 10.1371/journal.pone.0313269. eCollection 2024. PLoS One. 2024. PMID: 39642099 Free PMC article.
-
Host and HBV Interactions and Their Potential Impact on Clinical Outcomes.Pathogens. 2023 Sep 8;12(9):1146. doi: 10.3390/pathogens12091146. Pathogens. 2023. PMID: 37764954 Free PMC article. Review.
-
Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.J Clin Med. 2021 Dec 31;11(1):208. doi: 10.3390/jcm11010208. J Clin Med. 2021. PMID: 35011949 Free PMC article.
References
-
- Observatory I.-W.G.C. Globocan 2020 Database. [(accessed on 17 August 2020)]; Available online: https://gco.iarc.fr/
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources